Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB1080

Introduced
3/30/23  
Refer
3/30/23  

Caption

Cooper Davis Act

Impact

The bill will significantly alter the landscape for how electronic service providers interact with law enforcement concerning drug-related crimes. For instance, it will impose legal obligations to report certain violations promptly, with heavy penalties for non-compliance. Should the bill pass, it will bind companies to new responsibilities which may change their operational policies and procedures to ensure compliance. These changes are expected to bolster the federal government's capacity to monitor and combat drug-related crimes, thus affecting public health and safety standards.

Summary

SB1080, also known as the Cooper Davis Act, seeks to amend the Controlled Substances Act by imposing new reporting requirements on electronic communication service providers and remote computing services regarding certain violations related to controlled substances. The bill mandates that providers report to the Attorney General when they gain knowledge of violations such as the illegal sale, distribution, or manufacture of controlled substances, particularly counterfeit drugs. This aims to enhance law enforcement's ability to curb the illegal drug trade fueled by online activity.

Sentiment

The sentiment surrounding SB1080 appears to be generally supportive among lawmakers focused on enhancing drug law enforcement and tackling the current crisis of counterfeit pharmaceuticals. However, there are concerns raised about privacy implications and the burden it places on service providers—particularly regarding how data is managed and reported. Advocates argue that the bill is a necessary step toward safeguarding public health, while critics fear it may lead to overreach and unintended consequences for user privacy.

Contention

Some points of contention regarding SB1080 include the implications for user privacy, as the bill may require providers to retain and report user data that could be sensitive. Moreover, the introduced penalties for failure to report, which can amount to hundreds of thousands of dollars, raise concerns among service providers about their liabilities and operational capacities. The bill's ability to balance effective law enforcement against individual privacy rights remains a crucial debate that will likely continue as it moves forward.

Companion Bills

US HB8918

Related Cooper Davis and Devin Norring Act

Similar Bills

US HB3089

NDO Fairness Act

US HB5331

Government Surveillance Transparency Act of 2023

US HB3621

Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2023

US HB501

Block, Report, And Suspend Suspicious Shipments Act

US SB1950

TEST Act Temporary Emergency Scheduling and Testing of Fentanyl Analogues Act of 2023

US HB6028

States Reform Act of 2023

US HB5601

MORE Act Marijuana Opportunity Reinvestment and Expungement Act

US HB171

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.